Actavis is planning to increase its presence in Turkey next year and make a real difference within the country’s oncology sector. Drawing on the Company’s expertise in affordable, high quality and technologically advanced oncology products, Actavis Turkey will launch a range of oncology medicines in 2012, along with various other new products.
Supporting more than one million patients every year
Actavis CEO and Chairman Claudio Albrecht believes there is huge potential for growth within the Turkish oncology market. “Actavis helps more than one million oncology patients every year around the world, with medicine that’s made at our flexible, high capacity and high quality EU manufacturing sites. Actavis Turkey can offer added value in oncology, delivering great quality for patients at affordable prices.”
Leading generic pharmaceuticals specialist announces 14 new product launches in Turkey for 2012, with a strong emphasis on oncology.
Outlining the Company’s plans for 2012, Actavis Turkey Country Manager Serdar Sozeri confirmed that a major oncology offering would be launched in 2012. “The new molecules available to the Turkish market will include Docetaxel, Irinotecan, Gemcitabine, Vinorelbine, Fludarabine, Etoposide and Topotecan. These new oncology products will help support Turkish people in the battle against cancer, and for healthcare professionals there is the added advantage of Actavis’ innovative safety-enhancing developments.
Building on detailed consultation in more than 40 markets, Actavis continues to develop new and often unique oncology presentations. Recent developments include ready-to-use mini-bags and reformulations of old powder-form cytotoxic pharmaceuticals.
The world’s fourth biggest player in the industry, Actavis specialises in the development, manufacture and sale of first-class generic pharmaceuticals.
Revenues for Actavis Group are expected to top EUR2bn in 2012, with the Turkish market forecast to contribute around EUR38m. Globally, Actavis’ hospital business ranks amongst the top 10 hospital generics players, with 630 dedicated hospital employees present in more than 30 markets and two high-quality manufacturing sites in Italy and Romania. It has manufacturing capacity for 42 million vials and markets in excess of 150 hospital products, a number that is set to increase rapidly with hundreds of applications currently pending and an ambitious development pipeline.
Enquiries
Frank Staud
EVP Corporate Communications
Tel: +41 (0)79 230 9578
E-mail: fstaud@actavis.com